U.S., Sept. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07796256) titled 'A Phase 2 Study of SGB-9768 in Patients With Paroxysmal Nocturnal Hemoglobinuria' on Aug. 2... Read More
U.S., Sept. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07797998) titled 'Association of Diet and IBD' on Aug. 24. Brief Summary: The study investigate the nutritio... Read More
Singapore, Sept. 2 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) M... Read More
Singapore, Sept. 2 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig i... Read More
Singapore, Sept. 2 -- The Health Sciences Authority received information related to the study titled 'An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and ... Read More
U.S., Sept. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07796334) titled 'Colon Health Champion Program' on Aug. 27. Brief Summary: This is a single arm-proof-of-co... Read More
Singapore, Sept. 2 -- The Health Sciences Authority received information related to the study titled 'A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of ascim... Read More
Singapore, Sept. 2 -- The Health Sciences Authority received information related to the study titled 'A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with... Read More
U.S., Sept. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07796945) titled 'Human Neutrophil Lipocalin as an Aid in the Diagnosis of Bacterial Infection in the Emergen... Read More
Singapore, Sept. 2 -- The Health Sciences Authority received information related to the study titled 'A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with... Read More